Guilherme Perini, MD, PhD, explained the rationale behind the KEYFORM-008 trial, exploring how targeting LAG-3 can reverse checkpoint inhibitor resistance.
Guilherme Fleury Perini, MD, PhD
Advertisement
Articles by Guilherme Fleury Perini, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does LAG-3/PD-1 Inhibition Fit In PD-1–Refractory Hodgkin Lymphoma?
2
VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors
3
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations
4
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
5